Patient Education

AbstractThe progressive number of old adults with cognitive impairment worldwide and the lack of effective pharmacologic therapies require the development of non-…

Key PointsQuestionWhat is the safety, tolerability, and efficacy of N-acetylcysteine (NAC) for patients with hereditary cystatin C amyloid angiopathy (HCCAA)?…

AbstractThe amyloid hypothesis has been a leading narrative concerning the pathophysiological foundation of Alzheimer’s and Parkinson’s disease. At the two ends of…

AbstractYears of experience watching our patients progressively decline and die from complications of Alzheimer's disease (AD) has strongly motivated us to provide…

AbstractIntroductionThis prospective observational study of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) undergoing treatment with tafamidis aims at…

BackgroundAmyloidosis is a complex and rare disease requiring specialized, multidisciplinary care to effectively manage its diverse manifestations. Existing…

AbstractIntroduction: Three treatments for Alzheimer's disease have been approved in the United States. Data are lacking on the characteristics of the initial…

AbstractBackground and aimsHereditary transthyretin amyloidosis (ATTRv) should be considered in patients diagnosed with intravenous immunoglobulin (IVIg)-resistant…

AbstractBackground: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and frequently underdiagnosed cause of heart failure characterized by the…

AbstractTransthyretin cardiac amyloidosis (TTR-CA) is a pathological condition characterized by the accumulation of misfolded transthyretin (TTR) protein in the…